News list for "Wantai Bio"
On June 4th, Wantai Biotechnology announced that the nine-valent human papillomavirus vaccine (Escherichia coli) (trade name: Xinkening 9) declared by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has been approved for marketing. The vaccine is suitable for women aged 9-45. Among them, 9-17 years old can use the two-dose vaccination procedure, and 18-45 years old can use the three-dose vaccination procedure. Previously, only one nine-valent HPV vaccine ...
On August 26th, Wantai Bio announced in the evening that the application for marketing authorization of the nine-valent HPV vaccine jointly developed by Wantai Canghai, a wholly-owned subsidiary of the company, and Xiamen University has been accepted by the Drug Evaluation Center of the State Food and Drug Administration. According to the "Drug Registration Administration Measures", the State Food and Drug Administration will conduct a technical review of the safety, efficacy and quality control...
